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Background: Yttrium-90 (90Y) positron emission tomography with integrated computed tomography (PET/CT)
represents a technological leap from 90Y bremsstrahlung single-photon emission computed tomography with
integrated computed tomography (SPECT/CT) by coincidence imaging of low abundance internal pair production.
Encouraged by favorable early experiences, we implemented post-radioembolization 90Y PET/CT as an adjunct to 90Y
bremsstrahlung SPECT/CT in diagnostic reporting.
Methods: This is a retrospective review of all paired 90Y PET/CT and 90Y bremsstrahlung SPECT/CT scans over a 1-year
period. We compared image resolution, ability to confirm technical success, detection of non-target activity, and
providing conclusive information about 90Y activity within targeted tumor vascular thrombosis. 90Y resin microspheres
were used. 90Y PET/CT was performed on a conventional time-of-flight lutetium-yttrium-oxyorthosilicate scanner with
minor modifications to acquisition and reconstruction parameters. Specific findings on 90Y PET/CT were corroborated
by 90Y bremsstrahlung SPECT/CT, 99mTc macroaggregated albumin SPECT/CT, follow-up diagnostic imaging or review
of clinical records.
Results: Diagnostic reporting recommendations were developed from our collective experience across 44 paired scans.
Emphasis on the continuity of care improved overall diagnostic accuracy and reporting confidence of the operator. With
proper technique, the presence of background noise did not pose a problem for diagnostic reporting. A counter-intuitive
but effective technique of detecting non-target activity is proposed, based on the pattern of activity and its relation to
underlying anatomy, instead of its visual intensity. In a sub-analysis of 23 patients with a median follow-up of 5.4 months,
90Y PET/CT consistently outperformed 90Y bremsstrahlung SPECT/CT in all aspects of qualitative analysis, including
assessment for non-target activity and tumor vascular thrombosis. Parts of viscera closely adjacent to the liver remain
challenging for non-target activity detection, compounded by a tendency for mis-registration.
Conclusions: Adherence to proper diagnostic reporting technique and emphasis on continuity of care are vital to the
clinical utility of post-radioembolization 90Y PET/CT. 90Y PET/CT is superior to 90Y bremsstrahlung SPECT/CT for the
assessment of target and non-target activity.
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The science of yttrium-90 (90Y) radioembolization is rapidly
evolving. In suitable patients, 90Y radioembolization is an
effective treatment modality for inoperable liver malignan-
cies, and its expansion into organs other than the liver has
been described [1-5]. Contemporary techniques and clinical
outcomes are well described in recent literature [6-11]. 90Y
radioembolization is complex and requires close multi-
disciplinary coordination across all stages of its workflow,
described as a continuum of care [7].
90Y radioembolization is brachytherapy delivered by
90Y-labelled microspheres implanted permanently in the
target vascular bed following intra-arterial injection. The
microsphere biodistribution within the target arterial terri-
tory is dependent on the locoregional flow environment
distal to the point of injection. This in turn is influenced by
a myriad of inter-related biophysical variables such as the
catheter tip cross-sectional spatial location, injection rate
and timing interval, proximity to branching daughter ves-
sels, extent of shunting, cardiovascular status, particle load
and microembolization [12-14]. Such complexity means
that technical success should not be assumed without
some form of microsphere imaging. A technically unsuc-
cessful 90Y radioembolization may have prognostic impli-
cations for tumor response or non-target radiation injury.
In recent years, 90Y bremsstrahlung single-photon emis-
sion computed tomography with integrated computed
tomography (SPECT/CT) has been the modality-of-choice
for post-radioembolization microsphere imaging, for the
lack of a better alternative [8]. 90Y bremsstrahlung scintig-
raphy suffers from a low spatial resolution, ranging be-
tween 11 to 15 mm depending on the choice of energy
window, collimator, and image processing [15-17]. This
is due to its inherent technical limitation as a form of in-
direct imaging of a continuous scatter radiation spectrum
without a pronounced photopeak, resulting in a coarse
representation of the microsphere biodistribution. 90Y
bremsstrahlung activity on SPECT/CT often appears
smooth and diffuse, with ill-defined margins which are dif-
ficult to distinguish from closely adjacent activity foci. As
a result, assessment of activity within subcentimeter tu-
mors or tumor vascular thrombosis are often suboptimal
on 90Y bremsstrahlung SPECT/CT. Quantitatively, 90Y
bremsstrahlung scintigraphy is largely inaccurate despite
compensation techniques for attenuation, scatter, and
collimator-detector response, making it unsuitable for
dose–response analysis [18-20].
Positron emission tomography with integrated com-
puted tomography (PET/CT) represents a technological
leap from 90Y bremsstrahlung SPECT/CT, both qualita-
tively and quantitatively, allowing direct imaging of 90Y
microspheres. Although 90Y is predominantly a β− emitter,
coincidence imaging of 90Y is possible because of a minor
decay branch to the 0+ first excited state of zirconium-90followed by β−β+ internal pair production at a very low
branching ratio of 31.86 ± 0.47 × 10−6 [21-24]. However,
the clinical application of 90Y PET/CT has been fraught
with challenges. Today’s time-of-flight PET/CT scan-
ners use lutetium-based crystals due to its superior
timing resolution. Such crystals, such as lutetium-
yttrium-oxyorthosilicate (LYSO), contain 2.6% of nat-
urally occurring lutetium-176 (176Lu) which results in
a background activity of intrinsic true and random co-
incidences which cannot be distinguished from coinci-
dences by an external radioactive source [22,25]. This
issue was previously thought to be clinically irrelevant
until recent interest in 90Y PET/CT. In addition, the
low positron activity of 90Y and the intrinsic activity of
176Lu can have an impact on scatter correction. For
time-of-flight PET, several authors have computed the
scatter based on the PET activity [26-28]. Since the
scatter correction algorithm depends on the PET activ-
ity map, which is poor due to low signal and intrinsic
noise, scatter correction will be negatively affected.
The unfavorable combination of intrinsic background
activity and a very low positron fraction results in
reconstructed 90Y PET/CT images which at the outset,
seem uninterpretable due to high background noise.
Despite this, several institutions have published en-
couraging early experiences using 90Y time-of-flight
PET for post-radioembolization imaging [29-31]. These
early reports suggest that despite background noise, it is
possible to obtain high-resolution images of micro-
sphere biodistribution using conventional time-of-flight
PET scanners, with only minor adjustments to scan
technique and image reconstruction such as PET acqui-
sition time, number of bed positions, reconstruction it-
erations, and subsets. 90Y phantom studies of lutetium-
based time-of-flight PET/CT systems found the spatial
resolution to be 9.3 mm, and the minimum detectable
90Y radioconcentration of a 10-mm phantom sphere
was approximately 1 MBq/ml [23,32]. Count rate linear-
ity was maintained when tested up to 4.7 GBq, and de-
tector saturation from 90Y bremsstrahlung radiation
was not an issue [22,23,32-34].
For tumor dose quantification, several phantom studies
using various protocols on lutetium-based time-of-flight
PET/CT systems have recently been published. Carlier et al.
found activity quantification of phantom spheres to be feas-
ible at 90Y radioconcentrations greater than 2 MBq/ml,
with recovery coefficients of approximately 0.6 and 0.7 for
spheres of diameters 17 and 28 mm respectively [32].
Willowson et al. showed a phantom sphere of 90Y radio-
concentration 3.9 MBq/ml and diameter 37 mm to have a
recovery coefficient of approximately 0.8, and a trend was
observed for recovery coefficients to approach 1 with in-
creasing sphere size [33]. Goedicke et al. achieved a mean
quantitative error of +2.4% ± 3.4% standard deviation in a
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than 2.9 MBq/ml had quantitative errors less than 2%
[34]. Elschot et al. found the absorbed dose quantitative
error of a 37-mm diameter phantom sphere of 90Y
radioconcentration 2.4 MBq/ml to be −11% uncorrected
and +6% corrected for partial volume effects [35]. These
phantom studies suggest that tumor dose quantification
by 90Y PET may be feasible, and complements clinical re-
ports of 90Y PET tumor dose quantification correlating
well with treatment response [24,36,37].
On the basis of superior image resolution, quantitative
capability, and encouraged by favorable early experiences
[29-31], we recently introduced post-radioembolization
90Y PET/CT as an adjunct to 90Y bremsstrahlung SPECT/
CT in diagnostic reporting. This is a two-part retrospect-
ive report reviewing our experience over a 1-year period:
Part 1 focuses on qualitative analysis and diagnostic re-
porting; Part 2 analyzes tissue dose–response by 90Y PET
quantification and evaluates the accuracy of tumor pre-
dictive dosimetry [38].
Methods
Institutional review board approval was obtained for the
conduct and publication of this retrospective report
(CIRB 2010/781/C, SingHealth, Singapore), and all re-
search is in compliance with the Helsinki Declaration.
We recently introduced 90Y PET/CT as an adjunct to
90Y bremsstrahlung SPECT/CT for high resolution
imaging of microsphere biodistribution. Pairing 90YTable 1 Recommendations for diagnostic reporting of post-ra
Item Recommendation
Continuity of care Post-radioembolization 90Y P
who has followed through th
predictive dosimetry, to 90Y r
PET display threshold setting for non-target
90Y activity detection
For detection of non-target 9
display threshold setting to d
Criteria for technical success 1. 90Y activity present in the
coverage of large targeted tu
2. The absence of clinically si
3. All findings are in keeping
Criteria for a technically unsuccessful
90Y radioembolization
1. The complete, or near-com
or poor overall activity cover
2. The presence of any non-t
predicts a high likelihood of
3. Any other situation where
inconsistent with pre-therapy
Criteria for non-target 90Y activity 1. Non-random pattern of ac
2. Conforms morphologically
3. A plausible vascular etiolog
Criteria for noise spikes 1. Small, discrete, ovoid activ
2. Random pattern of distribu
3. No plausible vascular etioloPET/CT with 90Y bremsstrahlung SPECT/CT enabled
the trouble shooting of indeterminate findings on either
modality, and facilitated the learning of our nuclear
medicine physicians in the diagnostic reporting of 90Y
PET/CT. As there were no 90Y PET/CT protocols spe-
cific to our scanner make and model in prior literature,
our early scan protocols were based on publications of
other scanner types [22,29]. In the first few months after
implementation, our 90Y PET/CT protocol was continu-
ally refined by empirical adjustment of acquisition and
reconstruction parameters, with a primary emphasis on
visual image quality. The aim was to qualitatively achieve
a balance between image resolution and background
noise, of sufficient clarity for diagnostic reporting pur-
poses. Quantitative accuracy was not a consideration
during this early optimization phase.
Our PET/CT is the GE Discovery 690 (General Electric
Medical Systems, GEMS, Milwaukee, WI, USA). It uses
cerium-activated LYSO crystals, and its image reconstruc-
tion is a fully three-dimensional (3D) ordered subset ex-
pectation maximization (3D-OSEM) algorithm which
incorporates time-of-flight and point spread function in-
formation (GEMS name: VUE-point FX; Sharp-IR) [25].
The resulting image is corrected for attenuation, scatter,
randoms, dead time, and normalization [25]. 90Y PET was
acquired using positron fraction 3.186 × 10−5, half-life
64.1 h, 15 min per bed position, 1 to 2 bed positions from
the diaphragm downwards to cover the entire liver,
reconstructed with 3 iterations and 18 subsets. Our fulldioembolization 90Y PET/CT
ET/CT is best reported by the same attending nuclear medicine physician
e entire planning-therapy continuum from exploratory angiography,
adioembolization.
0Y activity, the operator should actively adjust the upper PET visual
eliberately increase the background noise to moderate levels.
majority of targeted tumors, or good overall activity
mors; and
gnificant non-target 90Y activity; and
with pre-therapy radiation planning expectations.
plete absence of 90Y activity in the majority of targeted tumors,
age of large targeted tumors; or
arget 90Y activity where 90Y PET dose quantification
clinically significant radiation toxicity; or
the 90Y activity biodistribution is adversely
radiation planning expectations.
tivity distribution; and
to an untargeted anatomical structure on CT; with or without
y to account for its presence.
ity foci; and
tion which do not conform to underlying anatomy on CT; and
gy to account for its presence.












Adrenal metastatic GIST 1
Tumor vascular thrombosis (n)
Hepatic portal vein 6






Organ other than liver 1







Range 1.5 to 24.2
Total injected 90Y activity (GBq)
Median 2.2
Range 1.1 to 5.0
Interval from radioembolization to PET (h)
Median 21.3
Range 4.7 to 24.0
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ung SPECT/CT was performed on a Philips Precedence
(Philips, Amsterdam, The Netherlands), which has a dual-
head gamma camera and 16-slice CT. A medium energy
general purpose collimator was used. Based on our phan-
tom studies, we centered our energy window at 80% ±
15% keV to capture the most prominent photopeak amidst
a continuous bremsstrahlung spectrum. Scans were ac-
quired in 128 frames over 360°, 20 s per frame; 3D-OSEM
reconstruction using Philips Astonish software; 3 itera-
tions and 8 subsets; matrix size 128 × 128; low-dose CT
for anatomical correlation and attenuation correction. All
paired 90Y PET/CT and 90Y bremsstrahlung SPECT/CT
scans were performed within 1 h of each other.
Diagnostic reporting for all paired scans were done in
consensus by an experienced team of nuclear medicine
physicians with cumulative experience of more than 200
90Y radioembolization cases over 5 years. As no prior
guidelines existed in literature for the diagnostic reporting
of post-radioembolization 90Y PET/CT, a gestalt interpret-
ation was applied to all paired scans based on a thorough
knowledge of the case-specific treatment intent, angio-
graphic and dosimetric factors. 90Y resin microspheres
(SIR-Spheres, Sirtex Medical Limited, New South Wales,
Australia) were used. Our predictive dosimetric protocol
was previously described, which involves catheter-directed
CT angiography for arterial territory delineation, quantita-
tive 99mTc macroaggregated albumin (MAA) SPECT/CT
of the target organ, and Medical Internal Radiation Dose
(MIRD) macrodosimetry to achieve artery-specific person-
alized radiation planning [11]. As our treatment paradigm
deviates considerably from conventional semi-empirical
methods, our nuclear medicine team emphasizes continu-
ity of care and an in-depth knowledge of case-specific
angiography, in close collaboration with our interventional
radiologists.
One of the qualitative study objectives was to compare
the ability of 90Y PET/CT versus 90Y bremsstrahlung
SPECT/CT in providing conclusive information about the
presence or absence of 90Y activity within targeted tumor
vascular thrombosis. We chose to evaluate tumor vascular
thrombosis because these are tumorous lesions within
small-to-medium calibre vessels which carry prognostic
significance [9]. Another qualitative study objective was to
compare the ability of 90Y PET/CT versus 90Y brems-
strahlung SPECT/CT in detecting non-target activity.
Where these were appropriate, specific findings on 90Y
PET/CT were corroborated by 90Y bremsstrahlung
SPECT/CT, 99mTc MAA SPECT/CT, follow-up diagnostic
sectional imaging (e.g. CT or MRI), or review of clinical
records for symptoms or endoscopy. Clinical toxicities at-
tributable to 90Y radioembolization were graded according
to the Common Terminology Criteria for Adverse Events
version 4.03 (CTCAE; National Institutes of Health,National Cancer Institute, USA). A retrospective review of
clinical records was performed for all patients to exclude
any clinically significant non-target activity undetected by
both imaging modalities. The accuracies of both modal-
ities were calculated by binary classification testing.
Our methods for the diagnostic reporting of target and
non-target activity are presented in Table 1. In the absence
of established diagnostic reporting guidelines, our methods
were heuristically formulated based on rational angio-
graphic and dosimetric principles from our collective ex-
perience across all paired scans. Using these guidelines, we
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and other general issues related to the complexity of 90Y
radioembolization. Thus, the presence of background noise
did not pose a problem for diagnostic reporting. In Table 1,
we propose an unconventional technique for non-target ac-
tivity detection, which counter-intuitively requires an in-
crease in noise levels by adjusting the visual display
threshold, but was effective in overcoming the problem of
background noise.
As outlined in Table 1, operator adjustment of the PET
visual display threshold was a key step to qualitatively dis-
tinguish between signal and noise for diagnostic reporting.
The lower PET visual display threshold was set to zero for
both target and non-target activity detection. For target
activity detection, the upper PET visual display threshold
setting was adjusted to reduce the background noise to a
minimum. On our system, we used the following upper
PET visual display threshold settings for target activity de-
tection: median 53% (7,000 kBq/ml), mean 54% (6,900
kBq/ml), 95% confidence interval (CI) 47% to 61% (5,900
to 7,900 kBq/ml).
For non-target activity detection, the upper PET visual
display threshold setting was adjusted to deliberately
increase the background noise to moderate levels. This
counter-intuitive technique was necessary because genuineFigure 1 Patient 23. (a) Multifocal HCC seen on catheter-directed CT ang
artery. Four small tumors are indicated by arrows. (b) Enlarged view of seg
closely adjacent tumors separated by approximately 3 mm. (c) Post-radioem
tumors, depicted in high resolution. (d) 90Y bremsstrahlung SPECT/CT was
small tumors, but was unable to confirm any focal activity within the othertrace non-target activity may appear visually less intense
than noise spikes (see “Discussion”). Therefore, if the upper
PET visual display threshold had remained at the settings
used to suppress background noise for target activity as-
sessment, it will be unlikely for visually subtle, trace non-
target activity to be detected by the operator. Albeit sub-
jective, this method improved the detection of non-target
activity with appropriate diagnostic technique (Table 1).
On our system, we used the following upper PET visual
display threshold settings for non-target activity detection:
median 14% (2,000 kBq/ml), mean 22% (2,200 kBq/ml),
95% CI 4 to 41% (1,200 to 3,100 kBq/ml). Non-target activ-
ity was sometimes more easily detected on the rotating
maximum intensity projection (MIP) than on the sectional
PET or PET/CT images. On the rotating MIP, any activity
in a non-random pattern protruding from the smooth out-
line of targeted tissue amidst background noise was
regarded as suspicious and pursued on sectional PET and
PET/CT images. The above data is tabulated in Additional
file 1: Table S1.
Terms and definitions
The following terms and definitions are used through-
out our two-part report. Predictive dosimetry refers to
personalized radiation planning guided by moderniogram of the replaced left hepatic artery, arising from the left gastric
ment IV shows the larger central tumor being flanked by two smaller,
bolization 90Y PET/CT confirms focal activity within the four small
barely able to detect subtle activity in the larger (arrow) of the four
three small tumors due to its low resolution.
Figure 2 Patient 20. (a) Large hypovascular HCC in the right lobe, seen on contrast-enhanced CT Abdomen. (b) Catheter-directed CT angiogram of the
right hepatic artery demonstrates tumor hypovascularity and delineates the target arterial territory. (c) 90Y PET/CT depicts, in high resolution, a rim-like
activity in the tumor periphery with a large area of relative central photopenia, typical of hypovascular tumors. (d) 90Y bremsstrahlung SPECT/CT poorly
demonstrates the peripheral activity due to its low image resolution and under-represents the extent of central photopenia.
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where intended absorbed doses are determined a priori
based on case-specific clinical, angiographic and dosi-
metric parameters, in accordance with the achievable
intent [11]. Target refers to the arterial territory intended
for 90Y radioembolization, represented by planning
target volumes used in artery-specific predictive dosi-
metry [11]. Non-target refers to unintended 90Y activity
beyond planning target volumes, e.g., stomach and duo-
denum, which also includes untargeted non-tumorous
liver due to microsphere reflux or arterio-portal
shunting. Technical success refers to the qualitative as-
sessment of a satisfactory 90Y activity biodistribution in
accordance with radiation planning expectations as seen
on post-radioembolization 90Y PET/CT, not to be con-
fused with ‘clinical success’ [8]. Our definition of tech-
nical success is slightly dissimilar to conventional
reporting standards [8] because angiographic appea-
rances alone at the conclusion of 90Y radioembolization
may not necessarily reflect the actual microsphere
biodistribution [12,14]. The planning-therapy con-
tinuum for 90Y radioembolization at our institution is a
seamless, integrated workflow for nuclear medicine
physicians with emphasis on continuity of care, a multi-disciplinary approach, open and continuous inter-
disciplinary communication, and predictive dosimetry.
Results and discussion
Results
A total of 63 90Y radioembolization procedures were
performed over a 1-year period. Of these, 44 (70%) paired
90Y PET/CT and 90Y bremsstrahlung SPECT/CT scans
were performed. Twenty-one of 44 paired scans were
performed using various 90Y PET/CT protocols during our
early optimization phase. After finalization of our scan
protocol, a further 23 paired scans were performed. For
data consistency, all case examples, statistical and dose–re-
sponse results presented in this two-part report were lim-
ited to the latter 23 patients only.
Of these 23 patients, 19 (83%) had hepatocellular
carcinomas (HCC), 2 had intra-hepatic cholang-
iocarcinomas, 1 had liver metastases from pancreatic
neuroendocrine cancer, and 1 had a bulky right adrenal
gland metastasis from gastrointestinal stromal tumor
(GIST) - a case of 90Y radioembolization of an organ
other than the liver. Median age was 64.5 years (mean
63.5 years; range 40 to 77 years); there were 16 (70%)
male patients. Tumor vascular thrombosis was present
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inferior vena cava in one; and all were HCCs. The me-
dian hepatopulmonary shunt fraction estimated by
99mTc MAA planar scintigraphy was 5.8% (mean 6.6%;
range 1.5% to 24.2%).
A total of 39 arterial territories were treated across 23
patients (mean 2; range 1 to 4), which included the right
inferior phrenic, right internal mammary, and right infer-
ior adrenal arteries. The median injected 90Y activity was
2.2 GBq (mean 2.4 GBq; range 1.1 to 5.0 GBq), and the
median time interval from 90Y radioembolization to 90Y
PET/CT was 21.3 h (mean 19.2 h; range 4.7 to 24.0 h).
One patient was deemed technically unsuccessful due to
non-target activity in the gastric and duodenal walls
resulting in CTCAE Grade 3 toxicity; all others were tech-
nically successful. All the above data are summarized in
Table 2 and presented in full detail in Additional file 1:
Tables S2 and S3.Figure 3 Patient 10. Portal vein tumor thrombosis in a large heterogeneou
demonstrates contrast enhancement within portal vein tumor thrombosis (arr
tumor thrombus in high resolution. (e, f) The same activity is poorly visualized90Y PET/CT outperformed 90Y bremsstrahlung SPECT/
CT in all aspects of qualitative analysis. Its image reso-
lution was consistently superior to 90Y bremsstrahlung
SPECT/CT (Figures 1 and 2), which also improved oper-
ator confidence in diagnostic reporting. Among 23 patients,
7 had tumor vascular thrombosis seen on diagnostic sec-
tional imaging (Additional file 1: Table S4). 90Y PET/CT
was able to provide conclusive information about the pres-
ence or absence of activity within targeted tumor vascular
thrombosis in all seven patients (Figure 3), whereas 90Y
bremsstrahlung SPECT/CT was conclusive in only three of
seven patients; the remaining four patients were indeter-
minate due to its low resolution. In two patients without
visually detectable activity on 90Y PET/CT within targeted
tumor vascular thrombosis, follow-up scans confirmed dis-
ease progression in these lesions (Figure 4). Therefore,
within the statistical limitations of our small dataset, 90Y
PET/CT had a 100% accuracy for the provision ofs HCC. (a, b) Catheter-directed CT angiogram of the right hepatic artery
ow). (c, d) 90Y PET/CT depicts focal 90Y activity within the portal vein
on 90Y bremsstrahlung SPECT/CT as subtle, ill-defined activity.
Figure 4 Patient 12. (a, b) Portal vein tumor thrombosis (arrow) in a multifocal HCC seen on portal venous phase of a triphasic CT liver. (c) 90Y
PET/CT demonstrates absent activity within the portal vein tumor thrombus. (d) The diffuse nature of 90Y bremsstrahlung SPECT/CT is unable to
resolve the absence of activity within the portal vein tumor thrombus. (e, f) Four months post-radioembolization, a follow-up triphasic CT liver in
the portal venous phase shows significant progression of portal vein tumor thrombosis, validating the 90Y PET/CT findings.
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activity within targeted tumor vascular thrombosis, com-
pared to only 30% for 90Y bremsstrahlung SPECT/CT (60%
sensitivity and positive predictive value; 0% specificity and
negative predictive value).
90Y PET/CT detected non-target activity in all eight of
eight patients, whereas 90Y bremsstrahlung SPECT/CT
detected only four of eight patients initially - a further
three were seen only with hindsight of 90Y PET/CT
findings (Additional file 1: Table S5). These eight cases
include the stomach (Figure 5), duodenum, chest wall
(Figure 6), kidney (Figure 7), untargeted liver, and
gallbladder. All 23 patients underwent a retrospective
review of clinical records to exclude any clinicallysignificant non-target activity undetected by both im-
aging modalities. Three of 23 patients were non-
residents who were discharged back to their home coun-
tries after 90Y radioembolization and were lost to follow-
up. Of the remaining 20 patients, there were no cases of
toxicity greater than or equal to CTCAE Grade 3 attrib-
utable to undetected non-target activity in extra-hepatic
viscera at a median follow-up of 5.4 months (mean 6.3
months, 95% CI 4.5 to 8.1 months). Therefore, within the
statistical limitations of our small dataset, 90Y PET/CT had
a 100% accuracy for non-target activity detection, compared
to 80% for 90Y bremsstrahlung SPECT/CT (50% sensitivity;
100% specificity and positive predictive value; 75% negative
predictive value).
Figure 5 Patient 17. 90Y radioembolization of a recurrent intra-hepatic cholangiocarcinoma. (a) Pre-radioembolization coeliac axis ‘C’ digital
subtraction angiography (DSA) shows the common hepatic artery bifurcating into the right hepatic and gastroduodenal arteries ‘GDA’, later
branching into the right gastroepiploic artery ‘RGE’. DSA at the conclusion of 90Y radioembolization demonstrated significant vascular stasis and
reflux of contrast into the gastroduodenal and right gastroepiploic arteries (images not shown). (b) Coronal view of post-radioembolization 90Y
PET/CT and its (c) MIP demonstrates in high resolution, non-target activity along the gastric greater curve ‘G’, antrum ‘A’ and proximal duodenum ‘D’.
(d) MIP of 90Y bremsstrahlung SPECT shows concordant non-target activity, but of lower intensity and resolution. By quantification 90Y PET activity,
detailed in Part 2 [38], the non-target mean absorbed doses to the gastric greater curve, gastric outlet, and proximal duodenum were approximately
49, 65, and 53 Gy, respectively. Within weeks, the patient developed persistent epigastric pain. (e) Gastroscopy at 3.3 months revealed extensive
inflammation along the stomach and proximal duodenum. A Forrest III ulcer was present in the pylorus (large arrow). The ulcer edge (small arrows)
was inflamed and indurated. (f) Photomicrograph (H&E stain; ×200) of the gastric biopsy showed edema, congestion, and diffuse lymphoplasmacytic,
eosinophilic, and neutrophilic infiltrates. A purple-staining resin microsphere (arrow) surrounded by a halo was seen in the lamina propria. The
surrounding gastric glands show flattening of the epithelium, dilatation, and reactive atypia, consistent with severe cellular injury.
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90Y is an imperfect PET tracer. However, its superior
image resolution makes it very attractive for clinical use.
With proper diagnostic reporting technique, 90Y PET/CT
consistently out-performed 90Y bremsstrahlung SPECT/
CT in high-resolution imaging to confirm technical suc-
cess, detection of non-target activity, and providingconclusive information about 90Y activity within targeted
tumor vascular thrombosis. These qualitative parameters
have prognostic implications which may impact patient
management early in the post-radioembolization period.
90Y radioembolization is complex, and continuity of care
is paramount to the clinical utility of 90Y PET/CT. This is
because case-specific issues occur throughout the planning-
Figure 6 Patient 22. 90Y radioembolization of part of a segment III HCC via the terminal branch of the right internal mammary artery (RIMA).
(a, b) Pre-therapy 99mTc MAA SPECT/CT demonstrates non-target activity in the right lower anterior chest wall (arrows), shunted from proximal
branches of the RIMA. (c, d) 90Y PET/CT depicts in high-resolution, non-target activity conforming to the anatomy of the right lower anterior
chest wall, concordant with 99mTc MAA SPECT/CT. The slight dissimilarity in chest wall activity biodistribution between 90Y PET/CT versus 99mTc
MAA SPECT/CT is due to local arterial flow changes after prophylactic bland embolization of proximal branches of the RIMA (images not shown).
(e, f) 90Y bremsstrahlung SPECT/CT was unable to detect any non-target activity in the chest wall due to its low image resolution.
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biodistribution, e.g., selective sparing of liver segments, vas-
cular stasis, risk of microsphere reflux, vessels-at-risk, on-
table changes to the intended vascular approach. The same
attending nuclear medicine physician who follows through
the entire planning-therapy continuum already has in mind
an expected activity biodistribution when reviewing the 90Y
PET/CT. This case-specific knowledge improves overall
diagnostic accuracy and operator confidence, and leads to
clinically meaningful reporting.Despite the superior image resolution of 90Y PET/CT
over 90Y bremsstrahlung SPECT/CT, parts of extra-
hepatic viscera which lie closely adjacent to the liver still
remain blind spots for non-target activity detection, e.g.,
gallbladder fundus, gastric lesser curve, pylorus, and prox-
imal duodenum. These often appear anatomically insepar-
able from the adjacent liver on 90Y PET/CT, making
assessment for non-target activity in these areas very chal-
lenging. This issue is further compounded by varying de-
grees of PET/CT mis-registration due to the relatively
Figure 7 Patient 9. 90Y radioembolization of an organ other than the liver. KIT-negative GIST with bulky metastasis to the right adrenal gland,
refractory to tyrosine kinase inhibitors. (a) Pre-radioembolization digital subtraction angiogram (DSA) with catheter tip in the right renal artery ‘R’
demonstrates the origin of the right inferior adrenal artery ‘A’ and the arterial trees of the adrenal tumor and right kidney. The catheter tip was
advanced deep into the right inferior adrenal artery for 90Y radioembolization. (b) Post-radioembolization DSA with no change in catheter tip
position demonstrates significant vascular stasis and reflux of contrast down the right inferior adrenal artery and distally into the terminal
branches of the right renal artery (arrows). (c, d) 90Y PET/CT depicts in high resolution, non-target activity conforming to the anatomy of the right
renal cortex (arrows). (e, f) On 90Y bremsstrahlung SPECT/CT, non-target activity was indistinguishable from adjacent activity bloom in the coronal
plane, but seen as low-grade, diffuse activity in the saggital plane (arrows).
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larly affect 90Y bremsstrahlung SPECT/CT and should
therefore not be viewed as a comparative disadvantage.
Despite background noise, 90Y PET/CT had a higher de-
tection rate for non-target activity than 90Y bremsstrahl-
ung SPECT/CT. Our counter-intuitive technique of
deliberately increasing background noise levels has proven
to be effective. Its rationale lies in our observation that
noise spikes may be of higher visual intensity than non-
target activity, as the latter depends on the quantity
of shunted microspheres and its 90Y radioconcentration
within the non-target arterial territory. This means that
visually subtle but genuine trace non-target activity may
appear less intense than background noise. Quantitative re-
construction methods proposed by Carlier et al. to distin-
guish signal from noise were not investigated in our study
[32]. Therefore, from a qualitative perspective, a diagnosis
of non-target activity should not be made on the basis of its
visual intensity, but on its pattern and whether it conforms
to underlying anatomy. The presence of a plausible vascular
etiology will greatly lend support to the diagnosis, although
this is not an essential criteria because it may not always be
possible to identify a culprit vessel upon retrospective re-
view of angiography.
The presence or absence of correlative clinical signs or
symptoms do not feature in our criteria for non-target
activity because clinical sequelae is a quantitative func-
tion of dose–response radiobiology over time, with no
bearing on the qualitative presence of non-target activity
at the time of scan. For example, it is common to detect
subtle non-target activity in an untargeted liver lobe due
to minor microsphere reflux or arterio-portal shunting,
with no clinically relevant sequelae. Another example is
the presence of mild non-target activity in the gallbladder
wall, without ensuing clinical cholecystitis. It follows that
the absence of correlative clinical signs or symptoms do not
invalidate a 90Y PET/CT diagnosis of non-target activity.
The detection of non-target activity should immedi-
ately be followed by an assessment of the risk of devel-
oping clinically significant radiation toxicity. Accurate
risk assessment facilitates appropriate action to be
undertaken early to mitigate potential radiation injury,
even if the patient is asymptomatic at the time of scan.
This should be based on 90Y PET quantification of the
non-target tissue absorbed dose, which is superior to
subjective visual assessment alone. Exceptions are cases
of visually subtle, trace non-target activity where the
absorbed doses are unlikely to be clinically relevant.
Similarly, it may sometimes be difficult to distinguish
noise spikes from genuine 90Y activity. However, such in-
determinate activity foci are usually too mild to result in
any clinically relevant toxicity even if genuine, and there-
fore do not impact post-radioembolization management.
The topic of 90Y PET quantification and its clinicalapplications in tissue dose–response assessment and
tumor predictive dosimetry are presented in part 2 [38].
Conclusions
Adherence to proper diagnostic reporting technique
and emphasis on continuity of care are vital to the clin-
ical utility of post-radioembolization 90Y PET/CT. With
proper reporting technique, the presence of background
noise did not pose a problem, and 90Y PET/CT consist-
ently out-performed 90Y bremsstrahlung SPECT/CT in
all aspects of qualitative analysis. 90Y PET/CT may
supersede 90Y bremsstrahlung SPECT/CT as the
modality-of-choice for post-radioembolization assess-
ment of microsphere biodistribution.
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